Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder

A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder

To evaluate the long-term efficacy of oral aripiprazole in pediatric participants for the treatment of Tourette's Disorder (TD).

Study Overview

• Status: Terminated
• Conditions: Tourette's Disorder (TD)
• Intervention / Treatment: Drug: Aripiprazole; Drug: Placebo

Detailed Description

This study will evaluate the long-term efficacy of oral aripiprazole in the treatment of pediatric participants with Tourette's Disorder (TD). The trial consists of 3 distinct phases: a pretreatment phase, open-label stabilization phase, and a double-blind randomized withdrawal phase.

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 4

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Ajax, Ontario, Canada, L1Z 0M1
      • Kids Clinic
    • Toronto, Ontario, Canada, M6J 3S3
      • Jodha Tishon Inc.
• Hungary
  • Budapest, Hungary, 1021
    • Vadaskert Alaptvany A Gyermekek Lelki Egeszsegeert
  • Budapest, Hungary, 1083
    • Semmelweis Egyetem - I. sz. Gyermekgyógyászati Klinika
• United States
  • California
    • Anaheim, California, United States, 92805
      • Advanced Research Center
    • Riverside, California, United States, 92506
      • CT Trials - Riverside
    • Santa Ana, California, United States, 92705
      • Syrentis Clinical Research
  • Connecticut
    • Norwich, Connecticut, United States, 06360
      • Comprehensive Research Center
  • Florida
    • Gainesville, Florida, United States, 32607
      • Sarkis Clinical
    • Hialeah, Florida, United States, 33013
      • Eastern Research
    • Hialeah, Florida, United States, 33012
      • Reliable Clinical Research
    • Saint Petersburg, Florida, United States, 33701
      • Rothman Center for Pediatric Neuropsychiatry
    • South Miami, Florida, United States, 33143
      • Quest Pharmaceutical Services - Miami Research Associates
  • Georgia
    • Atlanta, Georgia, United States, 30328
      • Pediatric and Adolescent Neurodevelopment Associates
    • Fayetteville, Georgia, United States, 30214
      • Inova Clinical Trials and Research Center
  • Illinois
    • Naperville, Illinois, United States, 60563
      • Baber Research Group
  • Michigan
    • Bloomfield Hills, Michigan, United States, 48302
      • Neurobehavioral Medicine Group
  • Nebraska
    • Lincoln, Nebraska, United States, 68526
      • Alivation
  • New Jersey
    • Mount Arlington, New Jersey, United States, 07856
      • The NeuroCognitive Institute
  • New York
    • New York, New York, United States, 10036
      • Manhattan Behavioral Medicine
    • New York, New York, United States, 10036
      • Mood Disorders Consulting Medicine
    • Rochester, New York, United States, 14618
      • Finger Lakes Clinical Research
  • North Carolina
    • Charlotte, North Carolina, United States, 28211
      • New Hope Clinical Research
    • Durham, North Carolina, United States, 27707
      • Triangle Neuropsychiatry
  • Ohio
    • Avon Lake, Ohio, United States, 44012
      • Quest Therapeutics of Avon Lake DBA Haidar Almhana Nieding
    • Cincinnati, Ohio, United States, 45219
      • University of Cincinnati
    • Cleveland, Ohio, United States, 44106
      • University Hospitals Case Medical Center
    • Garfield Heights, Ohio, United States, 44125
      • Charak Center for Health and Wellness
    • Middleburg Heights, Ohio, United States, 44130
      • North Star Medical Research
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73112
      • Sooner Clinical Research
    • Oklahoma City, Oklahoma, United States, 73103
      • IPS Research
    • Oklahoma City, Oklahoma, United States, 73112
      • ClinMed Research Associates, Inc.
    • Oklahoma City, Oklahoma, United States, 73112
      • Rivus Wellness and Research Institute
  • Texas
    • Austin, Texas, United States, 78759
      • BioBehavioral Research of Austin
    • Irving, Texas, United States, 75062
      • University Hills Clinical Research
    • Plano, Texas, United States, 75093
      • Psychiatric Medical Associates
    • San Antonio, Texas, United States, 78229
      • Clinical Trials of Texas
  • Utah
    • Orem, Utah, United States, 84058
      • Aspen Clinical Research - Orem
  • Virginia
    • Charlottesville, Virginia, United States, 22903
      • University of Virginia School of Medicine
    • Petersburg, Virginia, United States, 23805
      • Clinical Research Partners - Richmond
  • Washington
    • Everett, Washington, United States, 98201
      • Core Clinical Research
    • Spokane, Washington, United States, 99202
      • Palouse Psychiatry & Behavioral Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 4 years to 15 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• The participant is a male or female child or adolescent, 6 to 17 years of age (inclusive) at the time of signing the informed consent/assent.
• The participant meets current Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) diagnostic criteria for TD, documented at screening and made by an adequately trained clinician, as confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version.
• The participant has a Total Tic Score (TTS) ≥ 20 on the Yale Global Tic Severity Scale (YGTSS) at screening and baseline (Day 1).
• The participant, a caregiver, and the investigator must all agree that the presenting tic symptoms cause impairment in the participant's normal routines, which include academic achievement, occupational functioning, social activities, and/or relationships.
• Females of childbearing potential (all female participants ≥ 12 years of age and all female participants < 12 years of age if menstruation has started) must have a negative pregnancy test and must not be pregnant or lactating.
• Written informed consent must be obtained from the participant or a legally acceptable representative (eg, guardian or caregiver), in accordance with requirements of the trial site's institutional review board (IRB)/independent ethics committee (IEC) and local regulatory requirements, prior to the initiation of any protocol-required procedures. In addition, the participant, as required by the trial center's IRB/IEC, must provide informed assent at screening and as such must be able to understand that he or she can withdraw from the trial at any time.
• Ability, in the opinion of the principal investigator, of the participant and the participant's legally acceptable representative (e.g., guardian) or caregiver(s) to understand the nature of the trial and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, and discontinuation of prohibited concomitant medications, to read and understand the written word in order to complete participant-reported outcomes measures, and to be reliably rated on assessment scales.

Exclusion Criteria:

• The participant presents with a clinical presentation and/or history that is consistent with another neurologic condition that may have accompanying abnormal movements. These include, but are not limited to, the following: Transient tic disorder; Huntington's disease; Parkinson's disease; Sydenham's chorea; Wilson's disease; Mental retardation; Pervasive developmental disorder; Tardive dyskinesia; Traumatic brain injury; Stroke; Restless legs syndrome.
• The participant has a history of schizophrenia, bipolar disorder, or other psychotic disorder.
• Participants who receive psychostimulants for the treatment of attention-deficit hyperactivity disorder (ADHD) and who have developed and/or had exacerbations of the tic disorder after the initiation of stimulant treatment. (Note that participants with ADHD who are treated with psychostimulants and have not developed new tics or a worsening of their current tics can be included if all other enrollment obligations are met).
• The participant currently has a primary diagnosis that meets DSM-5 criteria for mood disorder.
• The participant has severe obsessive-compulsive disease, as evidenced by a Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) score > 16.
• The participant has taken aripiprazole within 1 month (30 days) of the screening visit.
• The participant has a history of neuroleptic malignant syndrome.
• Participant is a sexually active male or female of childbearing potential (FOCBP) (all female participants ≥ 12 years of age and all female participants < 12 years of age if menstruation has started) who will not agree to practice 2 acceptable methods of birth control or who will not remain abstinent during the trial and for 30 or 90 days following the last dose of Investigational medicinal product (IMP) for females and males, respectively. Abstinence will be permitted if it is confirmed and documented at every trial visit.
• The participant represents a significant risk of committing suicide based on history (suicide attempt in past 1 year).
• The participant has a body weight < 16 kg.
• Participants who have taken neuroleptic or antiparkinson drugs within 14 days prior to baseline.
• Participants requiring cognitive-behavioral therapy (CBT) for TD during the trial period. CBT for other nonexclusionary disorder must remain consistent through the trial.
• The participant has met DSM-5 criteria for any significant psychoactive substance use disorder within the past 3 months.
• A positive drug screen for cocaine, alcohol, or other drugs of abuse (excluding caffeine, nicotine, or prescribed psychostimulants for ADHD). Investigators can choose to repeat a positive drug screen one time during screening period after concurrence from the medical monitor. A second positive test for any drug of abuse would be exclusionary.
• Participant requiring medication not allowed per protocol.
• Use of any cytochrome P450 (CYP)2D6 and CYP3A4 inhibitors or CYP3A4 inducers within 14 days prior to baseline and for the duration of the trial.
• Other nutritional or dietary supplements and nonprescription herbal preparations for TD (eg, cannabinoids, N-acetylcysteine, omega-3 fatty acids, kava extracts, GABA supplements) within 7 days prior to baseline and for the duration of the trial, unless approved in advance by the medical monitor.
• The inability to swallow tablets or tolerate oral medication.
• Participant has participated in a clinical trial involving either study medication or interventional (non-medication) treatment for TD within the last 60 days.
• The following laboratory test results, vital signs and electrocardiogram (ECG) results are exclusionary: Platelets ≤ 75,000/mm^3; Hemoglobin ≤ 9 g/dL; Neutrophils, absolute ≤ 1000/mm^3; Aspartate aminotransferase > 3 × upper limit of normal (ULN) as defined by the central laboratory; Alanine aminotransferase > 3 × ULN as defined by the central laboratory; Creatinine ≥ 2 mg/dL; Diastolic blood pressure > 105 mmHg; Corrected QT interval ≥ 450 msec (males) or ≥ 470 msec (females) using the corrected QT interval for heart rate using Fridericia's formula

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Open Label Stabilization Phase: Aripiprazole; Participants began treatment with aripiprazole at a 2.0 mg/day dose, with the dose titrated to 5.0 mg/day after 2 days. Subsequent dose adjustments were based on the participant's weight to achieve optimum control of tics up to the maximum recommended doses based on the United States Labeling, up to Week 8 and then continued on the most stabilized dose up to minimum Week 14 or maximum Week 20. Participants who met stabilization criteria were randomized to Double-blind Randomization Phase.	Drug: Aripiprazole; Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.; Other Names: OPC-14597
Experimental: Double Blind Phase: Aripiprazole Full Dose; Participants who met stabilization criteria and randomized to receive full dose of aripiprazole i.e. 5 mg or 10 mg for <50 kg participants,and 10 mg or 20 mg for >50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.	Drug: Aripiprazole; Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.; Other Names: OPC-14597
Experimental: Double Blind Phase: Aripiprazole Half Dose; Participants who met stabilization criteria and randomized to receive half dose of aripiprazole i.e. 2 mg or 5 mg for <50 kg participants, and 5 mg or 10 mg for >50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.	Drug: Aripiprazole; Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.; Other Names: OPC-14597
Placebo Comparator: Double Blind Phase: Placebo; Participants who met randomization criteria and randomized to receive aripiprazole matching-placebo tablets, 2 daily, orally, up to 12 weeks in Double-Blind Phase.	Drug: Placebo; Participants received aripiprazole matching-placebo tablets, orally as per the regimen specified in the arm description.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Relapse During the Double-blind Randomized Withdrawal Phase	Relapse was defined as a loss of ≥ 50% of the improvement experienced during the open-label stabilization phase (i.e., improvement at the last assessment of Yale Global Tic Severity Scale (YGTSS) before randomization) on the Yale Global Tic Severity Scale Total Tic Score (YGTSS TTS). YGTSS provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic symptoms.	From Randomization up to 12 weeks in Double-blind Randomized Withdrawal Phase

Collaborators and Investigators

• Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Investigators: Study Director: Eva Kohegyi, MD, MS, Otsuka Pharmaceutical Development & Commercialization, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): October 13, 2018
• Primary Completion (Actual): June 30, 2020
• Study Completion (Actual): June 30, 2020

Study Registration Dates

• First Submitted: September 5, 2018
• First Submitted That Met QC Criteria: September 5, 2018
• First Posted (Actual): September 7, 2018

Study Record Updates

• Last Update Posted (Actual): March 9, 2021
• Last Update Submitted That Met QC Criteria: February 16, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Keywords: Pediatric; Aripiprazole; Tourette's Disorder
• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Basal Ganglia Diseases; Movement Disorders; Neurodegenerative Diseases; Heredodegenerative Disorders, Nervous System; Neurodevelopmental Disorders; Tic Disorders; Disease; Tourette Syndrome; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Antipsychotic Agents; Tranquilizing Agents; Psychotropic Drugs; Serotonin Agents; Antidepressive Agents; Dopamine Agonists; Dopamine Agents; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Dopamine D2 Receptor Antagonists; Dopamine Antagonists; Aripiprazole
• Other Study ID Numbers: 31-14-204; 2018-002270-48 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
• IPD Sharing Time Frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
• IPD Sharing Access Criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
• IPD Sharing Supporting Information Type: Study Protocol; Statistical Analysis Plan (SAP); Clinical Study Report (CSR)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No